treosulfan has been researched along with Acute Myelogenous Leukemia in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (16.00) | 29.6817 |
| 2010's | 11 (44.00) | 24.3611 |
| 2020's | 10 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beelen, D; Bethge, W; Blaise, D; Chevallier, P; Ciceri, F; de Witte, T; Ganser, A; Iacobelli, S; Koster, L; Kröger, N; Luft, T; Mufti, GJ; Nagler, A; Robin, M; Schwerdtfeger, R; Shimoni, A; Volin, L; Yakoub-Agha, I | 1 |
| Casper, J; Frietsch, JJ; Hilgendorf, I; Hochhaus, A; Köhne, CH; O'Hagan Henderson, S | 1 |
| Bassermann, F; Braitsch, K; Götze, KS; Herhaus, P; Hubbuch, M; Keller, U; Koch, K; Menzel, H; Schwarz, A; Verbeek, M | 1 |
| Basara, N; Baumgart, J; Beelen, DW; Benedetti, F; Bethge, W; Bieniaszewska, M; Casper, J; Ciceri, F; Dreger, P; Finke, J; Glass, B; Grigoleit, GU; Hilgendorf, I; Holler, E; Junghanß, C; Klein, A; La Rocca, U; Labussiere-Wallet, H; Markiewicz, M; Niederwieser, D; Patriarca, F; Pichlmeier, U; Rambaldi, A; Reményi, P; Russo, D; Schaefer-Eckart, K; Scheid, C; Socié, G; Stelljes, M; Stölzel, F; Stuhler, G; Verbeek, M; Wagner-Drouet, EM; Wulf, G | 1 |
| Bertz, H; Bornhäuser, M; Burchert, A; Dreger, P; Finke, J; Glass, B; Grishina, O; Hegenbart, U; Kobbe, G; Reicherts, C; Schmoor, C; Schub, N; Sohlbach, K; Stelljes, M; Wagner-Drouet, EM | 1 |
| Bazarbachi, A; Bethge, W; Bug, G; Carlson, K; Hilgendorf, I; Kaare, A; Kröger, N; Labopin, M; Mielke, S; Mohty, M; Nagler, A; Niittyvuopio, R; Reinhardt, HC; Savani, BN; Schäfer-Eckart, K; Spyridonidis, A; Stelljes, M; Verbeek, M | 1 |
| Bagnoli, F; Barbullushi, K; Bellani, V; Cassanello, G; Cavallaro, F; Galassi, G; Goldaniga, M; Onida, F; Saporiti, G; Serpenti, F | 1 |
| Shimoni, A | 1 |
| Dreger, P; Hegenbart, U; Herfarth, K; Luft, T; Müller-Tidow, C; Radujkovic, A | 1 |
| Oniashvilli, N; Pasvolsky, O; Raanani, P; Rozovski, U; Rubinstein, M; Sela-Navon, M; Shargian-Alon, L; Wolach, O; Yahav, D; Yeshurun, M | 1 |
| Apel, A; Bernardi, M; Bonini, C; Ciceri, F; Danylesko, I; Greco, R; Lo Russo, A; Lupo Stanghellini, MT; Nagler, A; Peccatori, J; Shem-Tov, N; Shimoni, A; Vago, L; Yerushalmi, R | 1 |
| Bittenbring, J; Brecht, A; Canaani, J; Ganser, A; Labopin, M; Labussière-Wallet, H; Mayer, J; Mohty, M; Nagler, A; Savani, B; Sheth, V; Shouval, R; Volin, L | 1 |
| Amit, O; Avivi, I; Chemnitz, JM; Hallek, M; Holtick, U; Moshe, Y; Ram, R; Scheid, C; Wolf, D | 1 |
| Beelen, D; Bochtler, T; Brecht, A; Bunjes, D; Eder, M; Einsele, H; Kröger, N; Labopin, M; Labussière-Wallet, H; Mohty, M; Nagler, A; Niederwieser, D; Saraceni, F; Savani, BN; Tischer, J | 1 |
| Appelbaum, FR; Bar, M; Baumgart, J; Deeg, HJ; Delaney, C; Estey, EH; Fang, M; Gutman, J; Gyurkocza, B; Maziarz, RT; Milano, F; Nemecek, ER; Pagel, JM; Ramakrishnan, A; Sandmaier, BM; Scott, B; Storer, BE; Wood, B | 1 |
| Baidildina, D; Balashov, D; Bobrynina, V; Boyakova, E; Glushkova, S; Ilushina, M; Kalinina, V; Kazachenok, A; Kurnikova, E; Laberko, A; Maschan, A; Maschan, M; Muzalevskii, Y; Novichkova, G; Olshanskaya, Y; Persiantseva, M; Shelikhova, L; Skvortsova, Y | 1 |
| Chakupurakal, G; Chemnitz, JM; Hallek, M; Herling, M; Holtick, U; Leitzke, S; Pflug, N; Scheid, C; Wolf, D | 1 |
| Appelbaum, FR; Bedalov, A; Deeg, HJ; Doney, KC; Flowers, ME; Guthrie, KA; Hilger, RA; Kovacsovics, TJ; Maziarz, RT; Nemecek, ER; Pagel, JM; Sanders, JE; Scott, BL; Sickle, EJ; Sorror, ML; Witherspoon, R; Wood, BL; Woolfrey, AE | 1 |
| Brossart, P; Chemnitz, JM; Hallek, M; Holtick, U; Krause, A; Scheid, C; Shimabukuro-Vornhagen, A; Theurich, S; von Lilienfeld-Toal, M | 1 |
| Baumgart, J; Beelen, DW; Blau, I; Bornhaeuser, M; Casper, J; Einsele, H; Freund, M; Giebel, S; Holowiecki, J; Kruzel, T; Larsson, K; Markiewicz, M; Mylius, HA; Pichlmeier, U; Ruutu, T; Schaefer-Eckart, K; Stuhler, G; Trenschel, R; Uharek, L; Volin, L; Wandt, H; Zander, AR | 1 |
| Danylesko, I; Nagler, A; Shem-Tov, N; Shimoni, A; Volchek, Y; Yerushalmi, R | 1 |
| Baumgart, J; Emmerich, B; Meinhardt, G; Oellerich, M; Schmidmaier, R | 1 |
| Aschan, J; Blau, I; Casper, J; Doelken, G; Freund, M; Giebel, S; Holowiecki, J; Knauf, W; Kroger, N; Ruutu, T; Schafer-Eckart, K; Volin, L; Wandt, H; Zander, A | 1 |
| Schaefer-Eckart, K; Wandt, H; Wilhelm, M | 1 |
| Hardan, I; Nagler, A; Rand, A; Shem-Tov, N; Shimoni, A; Yerushalmi, R | 1 |
7 trial(s) available for treosulfan and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial.
Topics: Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Transplantation Conditioning; Vidarabine | 2022 |
Thiotepa-fludarabine-treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial.
Topics: Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Retrospective Studies; Thiotepa; Transplantation Conditioning; Unrelated Donors; Vidarabine | 2022 |
Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Neoplasm, Residual; Prospective Studies; Recurrence; Remission Induction; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2014 |
Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Female; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Factors; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult | 2011 |
Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioning.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2012 |
Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity.
Topics: Adult; Aged; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2012 |
Treosulfan/fludarabine: a new conditioning regimen in allogeneic transplantation.
Topics: Busulfan; Humans; Leukemia; Leukemia, Myeloid, Acute; Leukocyte Transfusion; Lymphoma; Myelodysplastic Syndromes; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2004 |
18 other study(ies) available for treosulfan and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT.
Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Cyclophosphamide; Disease Progression; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Living Donors; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Registries; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2021 |
Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms.
Topics: Busulfan; Cytarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Recurrence; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2022 |
Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysis.
Topics: Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myeloproliferative Disorders; Neoplasm Recurrence, Local; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2022 |
Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT.
Topics: Acute Disease; Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Recurrence; Retrospective Studies; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2023 |
Treosulfan, thiotepa and fludarabine conditioning regimen prior to first allogeneic stem cell transplantation in acute myeloid leukemia and high-risk myelodysplastic syndromes: a single center experience.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thiotepa; Transplantation Conditioning; Vidarabine | 2023 |
Treosulfan-based or busulfan-based conditioning for allogeneic transplantation: the role of dose intensity.
Topics: Busulfan; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Transplantation, Homologous; Vidarabine | 2020 |
High leukemia-free survival after TBI-based conditioning and mycophenolate mofetil-containing immunosuppression in patients allografted for chronic myelomonocytic leukemia: a single-center experience.
Topics: Adult; Aged; Antilymphocyte Serum; Busulfan; Calcineurin Inhibitors; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Melphalan; Methotrexate; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Neoplasms, Second Primary; Proportional Hazards Models; Retrospective Studies; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2020 |
Sequential treatment with FLAG-IDA/treosulfan conditioning regimen for patients with active acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cohort Studies; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2020 |
Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning.
Topics: Adult; Aged; Busulfan; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Genotype; Hematopoietic Stem Cell Transplantation; HLA-C Antigens; Humans; Leukemia, Myeloid, Acute; Ligands; Male; Middle Aged; Myelodysplastic Syndromes; Receptors, KIR; Recurrence; Retrospective Studies; Siblings; Transplantation Conditioning; Unrelated Donors; Vidarabine; Young Adult | 2017 |
Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis.
Topics: Aged; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate; Transplantation Conditioning; Vidarabine | 2019 |
Sequential therapy for patients with primary refractory acute myeloid leukemia: a historical prospective analysis of the German and Israeli experience.
Topics: Adolescent; Adult; Aged; Busulfan; Female; Germany; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Israel; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Probability; Prognosis; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Whole-Body Irradiation; Young Adult | 2019 |
Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Europe; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine; Young Adult | 2019 |
TCR-alpha/beta and CD19 depletion and treosulfan-based conditioning regimen in unrelated and haploidentical transplantation in children with acute myeloid leukemia.
Topics: Adolescent; Antigens, CD19; Busulfan; Child; Child, Preschool; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Humans; Infant; Leukemia, Myeloid, Acute; Male; Receptors, Antigen, T-Cell, alpha-beta; Transplantation Conditioning; Transplantation, Haploidentical; Unrelated Donors; Young Adult | 2016 |
Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol substituting 4 Gy TBI with treosulfan in an elderly population with high-risk AML.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Retrospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation; Young Adult | 2017 |
Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation | 2012 |
Treosulfan-induced apoptosis in acute myeloid leukemia cells is accompanied by translocation of protein kinase C delta and enhanced by bryostatin-1.
Topics: Aged; Apoptosis; Bryostatins; Busulfan; Cell Line; Female; Humans; Lactones; Leukemia, Myeloid, Acute; Macrolides; Male; Middle Aged; Protein Kinase C; Protein Kinase C-delta; Protein Transport; Species Specificity | 2004 |
Two allogeneic hematopoietic stem cell transplantations without the use of blood-product support.
Topics: Adult; Busulfan; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Jehovah's Witnesses; Leukemia, Myeloid, Acute; Male; Middle Aged; Transplantation, Homologous | 2005 |
Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes.
Topics: Adult; Aged; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |